Core Insights - Cidara Therapeutics (CDTX) shares have increased over 173% this year and reached a five-year high due to plans for expanding testing of its non-vaccine flu prevention drug [1][4] - Following a meeting with the FDA, Cidara has accelerated its Phase 3 testing plans by six months, aiming to align with the Northern Hemisphere flu season [2] - The FDA has encouraged the inclusion of older adults in the study, and Cidara believes a single final-phase study of its drug, CD388, could suffice for approval [2] Financial Projections - RBC Capital Markets analyst Brian Abrahams projects that over 5 million people could be on the drug in the future, estimating potential worldwide sales of $3.78 billion [3] - Abrahams has raised his price target for Cidara stock from $115 to $137, rating it as an outperform [3] Stock Performance - Cidara stock surged more than 17% to $86.11, marking its highest point since August 2020, and has more than tripled year-to-date [4] - The stock has achieved a perfect IBD Digital Relative Strength Rating of 99, indicating top performance over the past 12 months [4]

Key Points aTyr Pharma's leading candidate is targeting a relatively large market with unmet needs. The biotech company is expected to release data from a phase 3 clinical trial soon. Though things look somewhat promising for the company, aTyr Pharma is a risky stock. 10 stocks we like better than aTyr Pharma › Some prominent biotech companies tend to capture the majority of investors' and analysts' attention compared to their industry peers. aTyr Pharma (NASDAQ: LIFE), a small-cap, clinical-stag ...

Core Viewpoint - Abivax SA has successfully completed an offering of American Depositary Shares (ADSs), raising gross proceeds of approximately $747.5 million (€637.5 million) following the full exercise of the underwriters' option to purchase additional ADSs [1][2]. Group 1: Offering Details - The offering included a total of 11,679,400 ADSs, with gross proceeds of approximately $747.5 million (€637.5 million) and estimated net proceeds of around $700.3 million (€597.2 million) after deducting underwriting commissions and offering expenses [2]. - The offering price for the additional ADSs was set at $64.00 per ADS, which corresponds to €54.58 per ordinary share, reflecting a premium of 21.0% over the volume weighted average price of the ordinary shares in the preceding trading sessions [4]. Group 2: Use of Proceeds - The company intends to apply the net proceeds from the sale of the additional ADSs on a pro rata basis to the uses identified in the base offering [3]. Group 3: Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases, with its lead drug candidate, obefazimod (ABX464), currently in Phase 3 clinical trials for ulcerative colitis [7].